Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01411280 · ClinicalTrials.gov registry record · Phase 3
Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)
A Phase 3 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT01411280: Completed Phase 3 study, sponsored by Temple University.
NCT01411280 is a Phase 3 study that has completed, run by Temple University. The registered enrollment target is 34 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01411280, a Phase 3 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether methylphenidate is effective in enhancing the cognitive performance of children with the HbSS or HbSC genotype of SCD who have sustained neurological complications on laboratory-based measures of sustained attention, reaction time, and executive functions, and indirectly, verbal short-term and long-term memory.
Interventions
- DRUG methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT01411280 record still lists
NCT01411280 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which methylphenidate is the first listed.
NCT01411280 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01411280 about?
NCT01411280 is a clinical study titled "Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)". The purpose of this study is to assess whether methylphenidate is effective in enhancing the cognitive performance of children with the HbSS or HbSC genotype of SCD who have sustained neurological complications on laboratory-based measures of sustained attention, reaction time, and executive functio...
What is the current status of trial NCT01411280?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2006-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT01411280?
The interventions under investigation include: methylphenidate (DRUG).
Who is sponsoring clinical trial NCT01411280?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01411280's enrollment target sits among peer trials
34 1905th of 2000 higher than 94 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia